Literature DB >> 4172137

Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.

A J Levi, S Sherlock, D Walker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4172137     DOI: 10.1016/s0140-6736(68)92292-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  65 in total

Review 1.  Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors:  L A Pagliaro; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1975-10

Review 2.  Altered hepatic blood flow and drug disposition.

Authors:  A S Nies; D G Shand; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

3.  The effect of cirrhosis on the disposition and elimination of clindamycin.

Authors:  G R Avant; S Schenker; R H Alford
Journal:  Am J Dig Dis       Date:  1975-03

4.  Editorial: Care in prescribing.

Authors: 
Journal:  Br Med J       Date:  1976-02-21

Review 5.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 6.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 7.  Survey of the human acetylator polymorphism in spontaneous disorders.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1984-08       Impact factor: 6.318

Review 8.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 9.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

10.  A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol.

Authors:  R A Branch; J James; A E Read
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.